Phase 3 N=52 Highdose Nicotine Patch Therapy for Smokeless Tobacco Use
Smokeless Tobacco Use
Primary: End of Treatment (Week 8) Point Prevalence Abstinence — 11; 6 participants — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=81 Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction
Tobacco Dependence
Primary: Tobacco Abstinence at 12 Weeks — 8; 5 participants
N/A N=30 Sugars in Cigarettes
Tobacco Use
Primary: Impact of Cigarette Sugar Content on Product Satisfaction. — 4.09; 3.89; 3.92; 4.39 units on a scale
Phase 4 N=179 Smoking Tobacco and Drinking Study
Smoking · Heavy Episodic Drinking
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at 3 Months — 3; 4 Participants
N/A N=30 Effects of Electronic Cigarette Flavors on Abuse Liability in Smokers (P3-Taste)
Electronic Cigarette Use
Primary: Intensity of Drug Purchase Task (DPT) — 172.20; 89.90; 60.83; 94.50 number of puffs
N/A N=22 Comparative Abuse Liability Among African American and White Smokers
Tobacco Use Disorder
Primary: Nicotine Delivery — 14.13; 6.79; 9.15 ng/mL — p=0.002
N/A N=33 The Abuse Liability of a Novel Heated Tobacco Product (IQOS) and Its Feasibility as a Menthol Cigarette Substitute
Tobacco Use
Primary: Percent Change in Average Daily Cigarette Use Per Day From Baseline — 36.8; 80.36 % reduction in cigarettes per day
N/A N=60 Comparison of the Substitution Between Different Tobacco/Nicotine Products as a Function of Tobacco-user Type
Cigarette Smoking · Nicotine Vaping
Primary: Nicotine/Tobacco Products Substitution — 12.11; 4.82; 25.28; 17.08 mg of nicotine purchased — p=0.9793
Early Phase 1 N=16 Nicotine's Potential Abuse With Menthol
Nicotine Dependence
Primary: Drug Effect Questionnaire - Stimulatory Effects — 39.37; 33.48; 32.35; 33.23 units on a scale — p=0.93
N/A N=359 Novel Determinants and Measures of Smokeless Tobacco Use: Study 1
Smokeless Tobacco Use · Tobacco Dependence
Primary: Extent of Toxicity: Mean of Median Values of NNK+NNN in 7 Smokeless Tobacco Brands — 2.4; 2.25; 3.19; 5.51 ug/g
Phase 4 N=90 Tobacco Use Treatment in Cancer Patients
Smoking, Cigarette
Primary: Smoking 7-Day Point Prevalence at 12 Weeks — 2; 2; 3 Participants
N/A N=31 Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking
Smoking
Primary: Breath Sample (Expired Carbon Monoxide) — 18.77; 31.07; 25.38; 30.49 parts per million — p=0.92
N/A N=85 Assessing Toxicity of Waterpipe Tobacco Smoking
Waterpipe Smoking
Primary: Comparing Cotinine Pre-to-post Change Between 2 Waterpipe Smoking Sessions: Heating Waterpipe Tobacco by (a) Charcoal vs (b) an Electric Head — 34.9; 26.4 ng/mL — p=0.115
N/A N=36 Palatability of Experimental Cigarettes - Study 2
Smoking
Primary: Change in UrineTotal Nicotine Equivalent (TNE) Between Baseline and Week 1 — -16.2; -7.6; 1.3 nmols/ml
Phase 4 N=226 Stress Neuroadaptation in Tobacco Dependence
Nicotine Dependence
Primary: Overall Stressor Reactivity — 25.1; 22.5; 32.3; 16.9 microvolts
Phase 3 N=270 Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
Smokeless Tobacco Use
Primary: Prolonged Smokeless Tobacco Abstinence at 3 Months — 65; 41 Participants — p=<0.05
N/A N=103 Addiction and Behavior Related to Menthol Cigarette Substitutes
Smoking (Tobacco) Addiction
Primary: Puffing Topography: Puff Duration — 1.99; 2.06; 2.66; 1.87 seconds
Phase 2 N=237 Efficacy of Varenicline for Smokeless Tobacco Use in India
Tobacco Use Disorder
Primary: 7-day Point Prevalence Smokeless Tobacco Abstinence Biochemically Confirmed With Urine Cotinine at the End of 12 Weeks of Treatment. — 30; 23 participants
N/A N=37 Cigarette Smoking Decision Study
Tobacco Smoking
Primary: Demand Intensity as Assessed by a Behavioral Economic Demand Curve — 4.709677419; 2.580645161 puff bouts
Phase 2 N=130 Health Effects of SLT, Cigarette Smoking, and New Tobacco Products
Nicotine Dependence
Primary: Toxicant Exposure by Products — 835.3; 782.1; 726.8; 0.157 ng/ml — p=0.002
N/A N=136 Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors
Tobacco Addiction · Dual Tobacco Use
Primary: Number of Days Using Alternative Products — 14; 26; 20 Number of days
N/A N=104 Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
Tobacco Use Disorder
Primary: Product Preference — 27; 23; 24; 24 participants
N/A N=139 Cigarette Smoking Among Young Adults
Cigarette Smoking · Smoking Behaviors
Primary: Puff Topography — 1108; 1045.2; 1084.6 mL
N/A N=484 Parent eReferral to Tobacco Quitline
Secondhand Smoke
Primary: Number of Parent Smokers Who Enrolled in Quitline — 209; 245; 24; 5 Participants
N/A N=231 A Study to Evaluate Changes in Smokers Using Oral Tobacco-derived Nicotine Products.
Tobacco Use
Primary: Summary of Urine Total NNAL Amount Excreted and Absolute Change From Baseline (ng/24 Hour) by Study Group and Study Day (mITT Population) — 511.889; 581.676; 548.751…
N/A N=76 Varenicline for the Treatment of Smokeless Tobacco
Nicotine Dependence
Primary: 7-day Point Prevalence All Tobacco Abstinence — 21; 16 participants — p=0.126
N/A N=67 Clinical Trial Tobacco Marijuana
Cannabis Use Disorder · Tobacco Use Disorder
Primary: Tobacco Quit Attempts — 13; 17 Participants — p== 0.33
N/A N=12 Effect of Smoking Exposure on Smoking Relapse Following Brief Abstinence - 2
Tobacco Use Disorder
Primary: Cigarette Choice After 3 Day Abstinence — 2.50; 3.67 number of cigarette choices (0-6)
Phase 2 N=114 N-acetylcysteine for Tobacco Use Disorder
Nicotine Dependence · Smoking
Primary: Number of Participants With Biochemically-verified Abstinence From Smoking on Days 1-3 of the Protocol. — 8; 6 Participants
Phase 4 N=181 Cannabis and Tobacco Co-use Study
Tobacco Use Disorder
Primary: Number of Participants With Biologically Verified 7-day Point Prevalence Tobacco Abstinence at the End of Treatment (Week 12) — 30; 40; 36; 42 Participants